Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Immunomedics, Inc.    IMMU

IMMUNOMEDICS, INC. (IMMU)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets

Immunomedics : Leaps Despite Q1 Loss

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 09:27pm CEST
Immunomedics, Inc. (NASDAQ: IMMU) shares spiked in Friday trading on first quarter numbers Total costs and expenses for the first quarter ended September 30, 2017 were $22.3 million, compared to $15.7 million for the same quarter in fiscal 2017, an increase of approximately 42%. Net loss attributable to stockholders was $118.7 million, or approximately $0.97 per share, for the first quarter ended September 30, 2017, compared to $16.2 million, or approximately $0.17 per share, for the same quarter in fiscal 2017, an increase of approximately 633%. Cash, cash equivalents, and marketable securities totaled $139.6 million as of September 30, 2017. Chairman Behzad Aghazadeh said, “During the quarter and over the course of the year, we have made significant progress toward preparing a BLA for accelerated approval of IMMU-132, our breakthrough therapy candidate for the treatment of late-stage metastatic triple-negative breast cancer (mTNBC). "IMMU-132 has shown a remarkable response rate in patients and we remain sharply focused on bringing this promising treatment to market as soon as possible. Notably, in the quarter, we completed a number of successful meetings with the (Food and Drug Administration) including a CMC and a pre-BLA meeting, where we received positive feedback on our proposed submission plans. As such, we remain on track to meet our stated goal of submitting our BLA filing in the first quarter.” Shares gained $2.03, or 19.4%, to $12.47.

Copyright © 2017 Baystreet.ca Media Corp. All rights reserved., source Standard Equities Feed

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on IMMUNOMEDICS, INC.
10/03IMMUNOMEDICS INC : Entry into a Material Definitive Agreement, Unregistered Sale..
AQ
09/28IMMUNOMEDICS INC : Change in Directors or Principal Officers (form 8-K)
AQ
09/13Immunomedics and Samsung BioLogics Announce Strategic Manufacturing Partnersh..
AQ
09/12IMMUNOMEDICS INC : Entry into a Material Definitive Agreement, Other Events, Fin..
AQ
09/12IMMUNOMEDICS : and Samsung BioLogics Announce Strategic Manufacturing Partnershi..
AQ
08/28IMMUNOMEDICS : Announces Participation in Upcoming Healthcare Conferences
AQ
08/23IMMUNOMEDICS : Fiscal 4Q Earnings Snapshot
AQ
08/23IMMUNOMEDICS INC : Change in Directors or Principal Officers (form 8-K)
AQ
08/23IMMUNOMEDICS : Management's Discussion and Analysis of Financial Condition and R..
AQ
08/23IMMUNOMEDICS INC : Results of Operations and Financial Condition, Financial Stat..
AQ
More news
News from SeekingAlpha
10/19Premarket analyst action - healthcare 
10/04Forensic Stock Selections For October - Positive Forensic Returns Averaging +.. 
09/24BIOTECH STOCKS : Niche Operators Scientifically, Competing Directly As Investmen.. 
09/17Premarket analyst action - healthcare 
09/12Immunomedics and Samsung Biologics announce strategic manufacturing partnersh.. 
Financials ($)
Sales 2019 30,6 M
EBIT 2019 -211 M
Net income 2019 -225 M
Finance 2019 301 M
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales 2019 135x
EV / Sales 2020 27,8x
Capitalization 4 428 M
Chart IMMUNOMEDICS, INC.
Duration : Period :
Immunomedics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IMMUNOMEDICS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 37,3 $
Spread / Average Target 57%
EPS Revisions
Managers
NameTitle
Michael Pehl President, Chief Executive Officer & Director
Behzad Aghazadeh Chairman
Usama Malik Chief Financial & Business Officer
Robert Iannone Chief Medical Officer, Head-Research & Development
Morris Z. Rosenberg Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
IMMUNOMEDICS, INC.46.66%4 241
CELLTRION, INC.--.--%28 844
IQVIA HOLDINGS INC29.16%26 016
LONZA GROUP23.59%24 556
INCYTE CORPORATION-31.18%13 698
SEATTLE GENETICS, INC.34.21%11 706